Effect of standard nicotinamide in the prevention of type 1 diabetes in first degree relatives of persons with type 1 diabetes

Autoimmunity

Volumn 39, Issue 4, 2006, Pages 333-340

  Cabrera Rode, Eduardo ^a   Molina, Gisela ^a   Arranz, Celeste ^a   Vera, Manuel ^a   González, Pedro ^b   Suárez, Rolando ^a   Prieto, Mirta ^c   Padrón, Saúl ^d   León, Rafael ^d   Tillan, Juana ^d   García, Igrid ^e   Tiberti, Claudio ^f   Rodríguez, Olga María ^g   Gutiérrez, Antonio ^h   Fernández, Tamara ^a   Govea, Amparo ^a   Hernández, José ⁱ   Chiong, Dania ^j   Domínguez, Emma ^a   Di Mario, Umberto ^f   Díaz Díaz, Oscar ^a   Díaz Horta, Oscar ^a   more..

^a INSTITUTO NACIONAL DE ENDOCRINOLOGÍA   (Cuba)

^b HOSPITAL PEDIÁTRICO DOCENTE WILLIAM SOLER   (Cuba)

^c Academic Paediatric Hospital Pedro Borrás   (Cuba)

^d CENTRO DE INVESTIGACIÓN Y DESARROLLO DE MEDICAMENTOS CIDEM   (Cuba)

^e Marianao Blood Bank   (Cuba)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g National Coordinating Centre for Clinical Trials   (Cuba)

^h Paediatric Hospital Eduardo Agramonte Piña   (Cuba)

ⁱ Paediatric Hospital Pepe Portilla   (Cuba)

^j Paediatric Hospital of Havana Centre   (Cuba)

more..

Author keywords

HLA; Insulin sensitivity; Islet associated antibodies; Nicotinamide; Prevention; Type 1 diabetes

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; GLUCOSE; HLA DR ANTIGEN; INSULIN; NICOTINAMIDE; PANCREAS ISLET CELL ANTIBODY; PLACEBO;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETOGENESIS; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; FEASIBILITY STUDY; FEMALE; GENOTYPE; GLUCOSE BLOOD LEVEL; HLA TYPING; HUMAN; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; MALE; MAXIMUM PERMISSIBLE DOSE; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET CELL; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL; RELATIVE;

ADOLESCENT; ADULT; AUTOANTIBODIES; BLOOD GLUCOSE; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLUCOSE TOLERANCE TEST; HLA-DR ANTIGENS; HUMANS; INSULIN; MALE; NIACINAMIDE; PREDIABETIC STATE; VITAMIN B COMPLEX;

EID: 33746994498     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.1080/08916930600738383     Document Type: Article

References (49)

1. Eisenbarth, GS. (1986) Type I diabetes mellitus. A chronic autoimmune disease N Engl J Med, 314, pp. 1360-1368.
2. Akerblom, HK and Knip, M. (1998) Putative environmental factor in type 1 diabetes Diabetes Metab Rev, 14, pp. 31-67.
3. Knip, M and Akerblom, HK. (1999) Environmental factors in the pathogenesis of type1 diabetes mellitus Exp Clin Endocrinol Diabetes, 107(Suppl 3), pp. S93-S100.
4. Hyoty, H and Taylor, KW. (2002) The role of viruses in human diabetes Diabetologia, 45, pp. 1353-1361.
5. Honeyman, MC and Coulson, BS and Stone, NL and Gellert, SA and Goldwater, PN and Steele, CE and (2000) Association between rotavirus infection and pancreatic isletautoimmunity in children at risk of developing type 1 diabetes Diabetes, 49, pp. 1319-1324.
6. Díaz-Horta, O and Bello, M and Cabrera-Rode, E and Suárez, J and Más, P and García, I and (2001) Echovirus 4 and type 1 diabetes mellitus Autoimmunity, 34, pp. 275-281.
7. Cabrera-Rode, E and Sarmiento, L and Tiberti, C and Molina, G and Barrios, J and Hernández, D and (2003) Type 1 diabetes islet associated antibodies in subjects infected by echovirus 16 Diabetologia, 46, pp. 1348-1353.
8. Rønningen, KS and Keiding, N and Green, A and on behalf of genomic marker contributorsand the EURODIAB ACA study group. (2001) Correlations between the incidence of childhood-onset type 1 diabetes in Europe and HLA genotypes Diabetologia, 44(Suppl 3), pp. B51-B59.
9. Kulmala, P and Savola, K and Reijonen, H and Veijola, R and Vähäsalo, P and Karjalainen, J and (2000) Genetic markers, humoral autoimmunity, and prediction of type 1 diabetes in siblings of affected children. Childhood diabetes in finland study group Diabetes, 49, pp. 48-58.
10. Krischer, JP and Cuthbertson, DD and Yu, L and Orban, T and Maclaren, N and Jackson, R and (2003) Screening strategies for the identification of multiple antibody-positive relatives of individuals with type 1 diabetes J Clin Endocrinol Metab, 88, pp. 103-108.
11. Achenbach, P and Warncke, K and Reiter, J and Naserke, HE and Williams, AJ and Bingley, PJ and (2004) Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics Diabetes, 53, pp. 384-392.
12. Colman, PG and McNair, P and Margetts, H and Schmidli, RS and Werther, GA and Alford, FP and (1998) The Melbourne pre-diabetes study: Prediction of type 1 diabetes mellitus using antibody and metabolic testing Med J Aust, 169, pp. 81-84.
13. Elliott, RB and Chase, HP. (1991) Prevention or delay of type (insulin-dependent) diabetes mellitus in children using nicotinamide Diabetologia, 34, pp. 362-365.
14. Elliott, RB and Pilcher, CC and Fergursson, DM and Steward, AW. (1996) A population based strategy to prevent insulin-dependent diabetes using nicotinamide J Pediatr Endocrinol Metab, 9, pp. 501-509.
15. The European Nicotinamide Diabetes Intervention Trial (ENDIT) Group. (2003) Intervening before the onset of type 1 diabetes: Baseline data from the European Nicotinamide Diabetes Intervention Trial (ENDIT) Diabetologia, 46, pp. 339-346.
16. Gale, EA and Bingley, PJ and Emmett, CL and Collier, T and European Nicotinamide Diabetes Intervention Trial (ENDIT) Group. (2004) European Nicotinamide Diabetes Intervention Trial (ENDIT): A randomized controlled trial of intervention before the onset of type 1 diabetes Lancet, 363, pp. 925-931.
17. Pozzilli, P and Browne, PD and Kolb, H. (1996) Meta-analysis of nicotinamide treatment in patients with recent-onset IDDM. The Nicotinamide Trialists Diabetes Care, 19, pp. 1357-1363.
18. Knip, M and Douek, IF and Moore, WPT and Gillmor, HA and McLean, AE and Bingley, PJ and (2000) Safety of high-dose nicotinamide: A review Diabetologia, 43, pp. 1337-1345.
19. Crino, A and Schiaffini, R and Manfrini, S and Mesturino, C and Visalli, N and Beretta Anguissola, G and (2004) A randomized trial of nicotinamide and vitamin E in children with recent onset type 1 diabetes (IMDIAB IX) Eur J Endocrinol, 150, pp. 719-724.
20. WHO. (1985) Diabetes mellitus: Report of a WHO study group. Geneva: World Health Organization.
21. Center for Research and Development of Medications (CIDEM). (1996) A report on standardization of a method for determination of N-methyl nicotinamide in urine. Havana: CIDEM.
22. Trinder, P. (1969) Determination of glucose oxidase with one alternative oxygen acceptor Ann Clin Biochem, 6, pp. 24-27.
23. Arranz, C and González-Suárez, RM. (1988) Insulin radioimmunoassay: A rapid method for separation of free and bound hormone Rev Cubana Invest Biomed, 7, pp. 150-156.
24. Matthews, DR and Hosker, JP and Rudenki, AS and Nailor, BA and Treacher, DF and Turner, RC. (1985) Homeostasis model assessment: Insulin resistance and beta cell function from fasting plasma glucose and insulin concentration in man Diabetologia, 28, pp. 412-419.
25. Bingley, PJ and Colman, PG and Eisenbarth, GS and Jackson, RA and McCulloch, DK and Riley, WJ and (1992) Standardization of IVGTT to predict IDDM Diabetes Care, 15, pp. 1313-1316.
26. Vardi, P and Dib, SA and Tuttleman, M and Connelly, JE and Grinbergs, M and Radizabeh, A and (1987) Competitive insulin autoantibody assay. Prospective evaluation of subjects at high risk for development of type 1 diabetes mellitus Diabetes, 36, pp. 1286-1291.
27. Grubin, CE and Daniels, T and Toivola, B and Landin-Olsson, M and Hagopian, WA and Li, L and (1994) A novel radioligand binding assay to determine diagnostic accuracy of isoform-specific glutamic acid decarboxylase antibodies in childhood IDDM Diabetologia, 37, pp. 344-350.
28. Verge, CF and Stenger, D and Bonifacio, E and Colman, PG and Pilcher, C and Bingley, PJ and (1998) Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: Combinatorial islet autoantibody workshop Diabetes, 47, pp. 1857-1866.
29. Terasaki, PI and Bernoco, D and Parks, MS and Oztruk, G and Iwaki, Y. (1978) Microdroplet testing for HLA-A, -B, -C, and -DR antigens Am J Clin Pathol, 69, pp. 103-120.
30. Bruning, JW and Douglas, R and Scholtus, M and Van Rood, JJ. (1972) Automatic reading and recording of the microlymphocytotoxicity test Tissue antigens, 2, pp. 473-477.
31. Böyum, A. (1968) Separation of leukocyte from blood and bone marrow Scand J Clin Lab Invest, 21(Suppl), pp. 7-97.
32. Mandrup-Poulsen, T and Reimers, JI and Andersen, HU and Pociot, F and Karlsen, AE and Bjerre, U. (1993) Nicotinamide treatment in the prevention of insulin-dependent diabetes mellitus Diabetes Metab Rev, 9, pp. 295-309.
33. Petley, A and Macklin, B and Renwick, AG and Wilkin, TJ. (1995) The pharmacokinetics of nicotinamide in humans and rodents Diabetes, 44, pp. 152-155.
34. Machin, D and Campbell, MJ. (1987) Statistical tables for the design of clinical trials. In (pp. 35-53). Oxford: Blackwell Scientific Publication.
35. LaGasse, JM and Brantley, MS and Leech, NJ and Rowe, RE and Monks, S and Palmer, JP and (2002) Successful prospective prediction of type 1 diabetes in schoolchildren through multiple defined autoantibodies: An 8-year follow-up of the Washington state diabetes prediction study Diabetes Care, 25, pp. 505-511.
36. Diabetes Prevention Trial-Type 1 Diabetes Study Group. (2002) Effects of insulin in relatives of patients with type 1 diabetes N Engl J Med, 346, pp. 1685-1691.
37. Polo, V and Saibene, A and Pontiroli, AE. (1998) Nicotinamide improves insulin secretion and metabolic control in lean type 2 diabetic patients with secondary failure to sulphonylureas Acta Diabetol, 35, pp. 61-64.
38. Vidal, J and Fernández-Balsells, M and Sesmilo, G and Aguilera, E and Casamitjana, R and Gomis, R. (2000) Effects of nicotinamide and intravenous insulin therapy in newly diagnosed type 1 diabetes Diabetes Care, 23, pp. 360-364.
39. Manna, R and Migliore, A and Martin, LS and Ferrara, E and Ponte, E and Marietti, G and (1992) Nicotinamide treatment in subjects at high risk of developing IDDM improves insulin secretion Br J Clin Pract, 46, pp. 177-179.
40. Lampeter, EF and Klinghammer, A and Scherbaum, WA and Heinze, E and Haastert, B and Giani, G and (1998) The deutsche nicotinamide intervention study: An attempt to prevent type 1 diabetes Diabetes, 47, pp. 980-984.
41. Beales, PE and Burr, LA and Webb, GP and Mansfield, KJ and Pozzilli, P. (1999) Diet can influence the ability of nicotinamide to prevent diabetes in non-obese diabetic mouse: A preliminary study Diabetes Metab Res Rev, 15, pp. 21-28.
42. Virtanen, SM and Knip, M. (2003) Nutritional risk predictors of β cell autoimmunity and type 1 diabetes at a young age Am J Clin Nutr, 78, pp. 1053-1067.
43. Mok, CC and Lau, CS. (2003) Pathogenesis of systemic lupus erythematosus J Clin Pathol, 56, pp. 481-490.
44. Krause, I and Tomer, I and Elias, D and Blank, M and Gilburg, B and Cohen, IR and (1999) Inhibition of diabetes in NOD mice by idiotypic induction of SLE J Autoimmun, 13, pp. 49-55.
45. Binley, PJ and Caldas, G and Bonfanti, R and Gale, EA. (1993) Nicotinamide and insulin secretion in normal subjects Diabetologia, 36, pp. 675-677.
46. Greenbaum, CJ and Kahn, SE and Palmer, JP. (1996) Nicotinamide's effects on glucose metabolism in subjects at risk for IDDM Diabetes, 45, pp. 1631-1634.
47. Skyler, JS and Krischer, JP and Wolfsdorf, J and Cowie, C and Palmer, JP and Greenbaum, C and (2005) Effects of oral insulin in relatives of patients with type 1 diabetes: The diabetes prevention trial-type 1 Diabetes Care, 28, pp. 1068-1076.
48. Rossini, AA. (2004) From beast to bedside: A commentary Diabetologia, 47, pp. 1647-1649.
49. Devendra, D and Liu, E and Eisenbarth, ES. (2004) Type 1 diabetes: Recent developments BMJ, 328, pp. 750-754.